EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis

Mingxi Xie, Joyce H S You iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mingxi Xie und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Cost-Benefit Analysis, Deprescriptions, Quality-Adjusted Life Years. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over-prescribing of proton-pump inhibitors (PPIs) is widely observed in older patients. Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. We aimed to examine the cost-effectiveness of PPI deprescribing service from the perspective of Hong Kong public healthcare provider. A decision-analytic model was constructed to examine the clinical and economic outcomes of PPI deprescribing service (deprescribing group) and usual care (UC group) in a hypothetical cohort of older PPI-users aged ≥65 years in the ambulatory care setting. The model inputs were retrieved from literature and public data. The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. Primary model outcomes were direct medical cost and quality-adjusted life-years (QALYs) loss. In base-case analysis, the deprescribing service (versus UC) reduced total direct medical cost by USD235 and saved 0.0249 QALY per PPI user evaluated. The base-case results were robust to variation of all model inputs in one-way sensitivity analysis. In probabilistic sensitivity analysis, the deprescribing group was accepted as cost-effective (versus the UC group) in 100% of the 10,000 Monte Carlo simulations. In conclusion, the PPI deprescribing service saved QALYs and reduced total direct medical cost in older PPIs users, and showed a high probability to be accepted as the cost-effective option from the perspective of public healthcare provider in Hong Kong.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsCost-Benefit AnalysisDeprescriptionsQuality-Adjusted Life YearsHumansAgedHong KongMaleFemaleAged, 80 and overCost-Effectiveness Analysis

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Joyce H S You

Zitieren

APA

Xie, M., & You, J. H. S. (2024). Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0311658

Vancouver

Xie M, You JHS. Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0311658

BibTeX
@article{Xie2024,
  author = {Xie, Mingxi and You, Joyce H S},
  title = {Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311658}
}
Kostenlos starten →